Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 5/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.76 |
| ▸ | BRAF | P15056 | 5/20 | 0.76 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.76 |
| ▸ | LCK | P06239 | 4/20 | 0.76 |
| ▸ | ABL1 | P00519 | 4/20 | 0.76 |
| ▸ | SRC | P12931 | 3/20 | 0.76 |
| ▸ | EPHB2 | P29323 | 3/20 | 0.76 |
| ▸ | BCR | P11274 | 3/20 | 0.76 |
| ▸ | ESYT2 | A0FGR8 | 2/20 | 0.76 |
| ▸ | NBAS | A2RRP1 | 2/20 | 0.76 |
| ▸ | CNOT1 | A5YKK6 | 2/20 | 0.76 |
| ▸ | TBKBP1 | A7MCY6 | 2/20 | 0.76 |
| ▸ | AGPS | O00116 | 2/20 | 0.76 |
| ▸ | MYO1F | O00160 | 2/20 | 0.76 |
| ▸ | SNAP23 | O00161 | 2/20 | 0.76 |
| ▸ | AP3B1 | O00203 | 2/20 | 0.76 |
| ▸ | PSMD12 | O00232 | 2/20 | 0.76 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.76 |
| ▸ | PGRMC1 | O00264 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024839 | 0.89 | MAPK14 (0.74) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL24532081 | 0.88 | BRAF (0.80) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL24532018 | 0.88 | MAPK14 (0.76) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL16111549 | 0.87 | MAPK14 (0.68) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL29931136 | 0.86 | ABL1 (1.00) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL16111548 | 0.86 | ABL1 (1.00) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL4696313 | 0.86 | POLB (0.59) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL22025318 | 0.85 | BRAF (0.68) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL4699731 | 0.85 | ABL1 (1.00) | DDR2MAPK14BRAFDDR1LCK | |
| SCHEMBL29358745 | 0.85 | ABL1 (1.00) | DDR2MAPK14BRAFDDR1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | DDR2 2306/4885MAPK14 1253/4885BRAF 5/4885 |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | DDR2 2054/4885MAPK14 141/4885BRAF 65/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | DDR2 2054/4885MAPK14 141/4885BRAF 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.